88 Chapter 4 Table 1. Pre-radiotherapy sociodemographic and clinical characteristics of the patient population. (continued) Patients without follow-up Patients with 3 months follow-up Patients with ≥11 months follow-up Previous brain RT, n (%) 2 (8) 7 (19) 2 (14) Previous BMs resection, n (%) 7 (29) 10 (28) 4 (29) Previous immuno-/ chemotherapy, n (%) 18 (75) 10 (28) 9 (64) Type of RT SRS 19 (79) 34 (94) 14 (100) WBRT 4 (17) 2 (6) 0 (0) WBRT + SRS 1 (4) 0 (0) 0 (0) Dexamethasone use prior to RT, mg/day, median (IQR) 4 (0-4) 0 (0-4) 1 (0-4) Symptomatic BMs at diagnosis, n (%) 16 (67) 21 (58) 8 (57) Epilepsy c 3 (19) 8 (38) 4 (50) Motor c 5 (31) 7 (33) 3 (38) Sensory c 0 (0) 3 (14) 1 (13) Balance c 5 (31) 4 (19) 2 (25) Language c 0 (0) 2 (10) 1 (13) Visual c 4 (25) 4 (19) 2 (25) Cognitive c 6 (38) 3 (14) 1 (13) Headache c 5 (31) 7 (33) 2 (25) Other c 5 (31) 4 (19) 1 (13) aAccording to Verhage classification30, bself-reported,cPercentage of patients with symptomatic BMS at diagnosis. Note: Due to rounding, not all percentages add up to 100%. Abbreviations: BMs, brain metastases; IQR, interquartile range; RT, radiotherapy; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy. Subjective cognitive functioning Pre-radiotherapy Pre-radiotherapy subjective performance of a larger sample has been reported previously.23 Of the currently included sample, 11/36 (31%) reported stable subjective cognitive performance across all domains, while the majority of patients (24/36, 67%), report lower subjective cognitive performance than their premorbid levels on at least one cognitive domain (Supplementary Figure 1). Declines were
RkJQdWJsaXNoZXIy MTk4NDMw